TWiV 724: COVID-19 clinical update #51 with Dr. Daniel Griffin
Feb 27, 2021•37 min•Ep. 724
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In COVID-19 clinical update #51, Daniel Griffin reviews use of two masks, effectiveness of testing in nursing homes, updates on vaccines, use of nonsteroidal anti-inflammatory drugs, little effect of vitamin D and remdesivir in clinical studies, and a long COVID research initiative from NIH.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Updated NYC mask guidance (NYC Health)
- Two masks recommended (CDC)
- Effectiveness of testing in nursing homes (Clin Inf Dis)
- Vaccine reactogenicity and antibody response after COVID-19 (medRxiv)
- Bamlanivimab alone or with Etesevimab (JAMA)
- Non-steroidal anti-inflammatory drugs and death (BMJ)
- Budesonide and COVID-19 (medRxiv)
- No effect of vitamin D high dose (JAMA)
- Remdesivir little effect on hospitalized patients (NEJM)
- Sequelae 6 months after infection (JAMA)
- Long COVID initiative (NIH)
- Letters read on TWiV 724
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
For the best experience, listen in Metacast app for iOS or Android